Skip to main content
    T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.15
    -0.02 (-9.65%)

    Market Cap: $10.89M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Tscan Therapeutics Inc (TCRX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Tscan Therapeutics are Tvardi Therapeutics (TVRD), Quantum BioPharma (QNTM) and Marker Therapeutics (MRKR). By market cap, Tscan Therapeutics ranks 6th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.

    Peer Comparison

    TCRX's ROIC of -129.7% is above the peer median of -281.4%, and its revenue growth of -65.8% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Tscan Therapeutics (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Transcode Therapeutics Inc (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    Lantern Pharma Inc (LTRN)$6.47MN/AN/A0.0%N/A0.0%0.00%
    Peer median$10.26MN/A15.5x0.0%-281.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Tscan Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors
    Intensity Therapeutics, Inc. Common stock (INTS)
    Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems.
    INTS competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Transcode Therapeutics Inc (RNAZ)
    TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic...
    RNAZ competitors
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    Lantern Pharma Inc (LTRN)
    Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics...
    LTRN competitors

    Frequently Asked Questions About TCRX

    Who are Tscan Therapeutics' main competitors?

    The companies most similar to Tscan Therapeutics include Tvardi Therapeutics (TVRD), Quantum BioPharma (QNTM), Marker Therapeutics (MRKR), GT Biopharma (GTBP) and Intensity Therapeutics, Inc. Common stock (INTS), listed from the closest match.

    Who is Tscan Therapeutics' biggest competitor?

    Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Tvardi Therapeutics (TVRD) is the closest match by business profile, size, sector and industry.

    How does TCRX stock compare with its competitors?

    TCRX's P/S is 3.6x against a peer median of 15.5x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Tscan Therapeutics' competitors pays a higher dividend?

    Tscan Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Tscan Therapeutics bigger than its competitors?

    No. Tscan Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.